Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Global Clinical Trials Review, H1, 2016

Description: Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Global Clinical Trials Review, H1, 2016

Summary

Our clinical trial report, "Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Global Clinical Trials Review, H1, 2016" provides an overview of Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) clinical trials scenario. This report provides top line data relating to the clinical trials on Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). Clinical Trial Reports are generated using Our proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months

Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level

Contents:

List of Tables
List of Figures
Report Guidance
Clinical Trials by Region
Clinical Trials and Average Enrollment by Country
Top Five Countries Contributing to Clinical Trials in Asia-Pacific

Top Five Countries Contributing to Clinical Trials in Europe

Top Countries Contributing to Clinical Trials in North America

Top Five Countries Contributing to Clinical Trials in Middle East and Africa

Top Five Countries Contributing to Clinical Trials in Central and South America

Clinical Trials by G7 Countries: Proportion of Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) to Oncology Clinical Trials

Clinical Trials by Phase in G7 Countries

Clinical Trials in G7 Countries by Trial Status

Clinical Trials by E7 Countries: Proportion of Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) to Oncology Clinical Trials

Clinical Trials by Phase in E7 Countries

Clinical Trials in E7 Countries by Trial Status

Clinical Trials by Phase

In Progress Trials by Phase

Clinical Trials by Trial Status

Clinical Trials by End Point Status

Subjects Recruited Over a Period of Time

Clinical Trials by Sponsor Type

Prominent Sponsors

Top Companies Participating in Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics Clinical Trials

Prominent Drugs

Latest Clinical Trials News on Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)

Jun 20, 2016: Cellectis Announces First Patient Treated in Phase 1 Trial of UCART19 in Pediatric Acute B Lymphoblastic Leukemia (B-ALL)

Jun 12, 2016: Pfizer Announces Final Results From Inotuzumab Ozogamicin Pivotal Phase 3 Study In Adults With Relapsed/Refractory Acute Lymphoblastic Leukemia

Jun 10, 2016: BLINCYTO (Blinatumomab) Improved Overall Survival In Patients With B-Cell Precursor Acute Lymphoblastic Leukemia

Jun 10, 2016: Syros Pharmaceuticals Presents Data Demonstrating Significant Anti-Tumor Activity of its Lead Drug Candidate SY-1365 at 21st Congress of the European Hematology Association

Jun 10, 2016: Karyopharm Therapeutics Presents data on KPT-8602 at 2016 European Hematology Association Annual Meeting

Jun 04, 2016: Juno Therapeutics’ Investigational CAR T Cell Product Candidate JCAR015 Shows High Response Rates in Adults with B-cell ALL
Jun 04, 2016: Juno Therapeutics To present Data on JCAR017 at the 52nd Annual Meeting of the American Society

Jun 02, 2016: Kiadis Pharma announces its decision to file for marketing authorization with the European Medicines Agency (EMA) for ATIR101 in blood cancers

Jun 02, 2016: Seattle Children T-Cell Immunotherapy Clinical Trial for Children With Relapsed Leukemia Shows 93% Complete Remission Rate

May 31, 2016: Kite Pharma to Highlight Key Data from Engineered CAR T Cell Therapy Pipeline at the 2016 American Society of Clinical Oncology Annual Meeting

May 19, 2016: Syros Pharmaceuticals to Present on SY-1365 at 21st Congress of the European Hematology Association

May 18, 2016: Juno Therapeutics to Highlights New Efficacy, Safety, and Durability data for JCAR-014 at the 2016 American Society of Clinical Oncology Annual Meeting

May 18, 2016: Juno Therapeutics to Highlight First clinical results for JCAR017 at the 2016 American Society of Clinical Oncology Annual Meeting

May 18, 2016: Juno Therapeutics to Highlight JCAR-015 at the 2016 American Society of Clinical Oncology Annual Meeting

Apr 20, 2016: Juno Therapeutics Presents Clinical Data of JCAR018 at American Association for Cancer Research (AACR) Annual Meeting 2016

Apr 18, 2016: Immunomedics Announces Potent Anti-Tumor Activities with IMMU-114 in Preclinical Study in Acute and Chronic Leukemia

Apr 14, 2016: Juno Therapeutics Announces Updated clinical data for CD22 CAR T cell product candidate, JCAR018 at the American Association for Cancer Research Annual Meeting

Apr 04, 2016: Kiadis Pharma presents positive data on the primary endpoint of its single dose Phase II trial with ATIR101

Clinical Trial Profile Snapshots

Appendix

Abbreviations

Definitions

Research Methodology

Secondary Research

About us

Contact Us

Disclaimer

Source

List of Tables

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics, Global, Clinical Trials by Region, 2016*

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics, Global, Clinical Trials and
Average Enrollment by Top Countries, 2016*

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016*

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2016*

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics Clinical Trials, Europe, Top Five Countries, 2016*

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics Clinical Trials, North America, Top Countries, 2016*

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2016*

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2016*

Proportion of Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) to Oncology Clinical Trials, G7 Countries (%), 2016*

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics, G7 Countries, Clinical Trials by Phase, 2016*

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016*

Proportion of Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) to Oncology Clinical Trials, E7 Countries (%), 2016*

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics, E7 Countries, Clinical Trials by Phase, 2016*

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016*

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics, Global, Clinical Trials by Phase, 2016*

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics, Global, Clinical Trials In Progress by Phase 2016*

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics, Global, Clinical Trials by Trial Status, 2016*

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics Clinical Trials, Global, by End Point Status, 2016*

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2016*

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics Clinical Trials, Global, Key Sponsors, 2016*

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016*

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics Clinical Trials, Global,
Ongoing Clinical Trials by Prominent Drugs, 2016*

List of Figures

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics, Global, Clinical Trials by Region (%), 2016*

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016*

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016*

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2016*

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2016*

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics Clinical Trials, North America, Top Countries (%), 2016*

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2016*

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2016*

Proportion of Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) to Oncology Clinical Trials, G7 Countries (%), 2016*

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics, G7 Countries, Clinical Trials by Phase, 2016*

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016*

Proportion of Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) to Oncology Clinical Trials, E7 Countries (%), 2016*

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics, E7 Countries, Clinical Trials by Phase, 2016*

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016*

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics, Global, Clinical Trials by Phase (%), 2016*

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics, Global, Clinical Trials In Progress by Phase, 2016*

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics, Global, Clinical Trials by Trial Status, 2016*

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics Clinical Trials, Global, by End Point Status, 2016*

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2016*
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics Clinical Trials, Global, Key Sponsors, 2016*

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016*

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016*

Methodology

Ordering:

Order Online - [http://www.researchandmarkets.com/reports/3788426/](http://www.researchandmarkets.com/reports/3788426/)

Order by Fax - using the form below

Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Global Clinical Trials Review, H1, 2016
Web Address: http://www.researchandmarkets.com/reports/3788426/
Office Code: SCH32TJN

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Quantity</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User:</td>
<td>USD 2500</td>
</tr>
<tr>
<td>Electronic (PDF) - Site License:</td>
<td>USD 5000</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide:</td>
<td>USD 7500</td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: Mr [] Mrs [] Dr [] Miss [] Ms [] Prof []
First Name: _______________________________ Last Name: _______________________________
Email Address: * _______________________________
Job Title: _______________________________
Organisation: _______________________________
Address: _______________________________
City: _______________________________
Postal / Zip Code: _______________________________
Country: _______________________________
Phone Number: _______________________________
Fax Number: _______________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:
Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: 

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World